Strategy

2026 Japan–Korea Sector Priorities: Follow the Money Before Ad Spend

A scorecard for finding high-value marketing clients using contribution margin, operational readiness, measurability, and partner need—not market size alone.

10 min read2026-08-21Reviewed 2026-08-21By RIVACTA Team

The short answer

RIVACTA's first priority is Korean medical-beauty providers ready to serve Japanese patients; the second is established K-beauty brands with viable Japan unit economics. Japanese beauty, consumer, and food brands entering Korea are a selective third priority when local ownership and operating budgets are confirmed. High category ad spend alone does not prove an individual company can fund or benefit from a cross-border partner.

Industries with the largest money flows are not automatically the companies most able to pay RIVACTA. Strong demand can still destroy value when margins, compliance, logistics, consultation, or customer support are not ready.

We score market demand, customer value or contribution margin, need for an external partner, measurability, operational readiness, and RIVACTA delivery fit separately. The ranking below is RIVACTA's inference from public evidence, not an official market ranking.

What are the 2026 execution priorities?

Korea received more than 2.01 million foreign patients in 2025, while Japanese visitors recorded KRW 279.6 billion in medical-category card spending in 2024. Korean cosmetics exports also reached a record in 2025. These are strong demand signals, but readiness and economics decide whether to launch.

RIVACTA sales and content priority
PriorityTargetMoney-flow signalLaunch gate
P0Korean medical beauty ready for Japanese patientsHigh customer value and measurable consultation-to-visit journeyPatient-acquisition process, Japanese consultation, aftercare, compliance owner
P1K-beauty entering JapanExport growth and repeat-purchase potentialClaims, supply, post-return margin, Japanese CS, channel data
Selective P2Japanese beauty, consumer, and food brands entering KoreaGrowing trade and investment signalsKorea owner, regulatory and distribution budgets, inventory and CS
WatchK-food, franchises, IPOpportunity with uneven margin and distribution structuresProject-by-project diagnostic
DeprioritizeGaming, fintech, manufacturing, enterprise procurementLarge markets or ad budgets may existPoor fit with current scope and sales cycle

How do we verify ability to pay?

Revenue and industry ad-spend averages are insufficient. Verify seven separate budgets: paid diagnostic, partner fee, media, localization and production, compliance and specialists, logistics/inventory/returns or patient operations, and internal staff or customer support.

  • Can fund execution dependencies separately from the partner fee
  • Has a CAC ceiling based on contribution margin after returns and fees
  • Can track a consultation, booking, sale, or repeat purchase within 90 days
  • Has named owners for compliance, CS, inventory, or aftercare

Why does high ad spend not equal a good client?

Food and cosmetics have large shares of Japan's advertising market, and internet ad spend exceeded JPY 4 trillion. That shows category intensity, not a specific buyer's readiness. If the seven budgets and operating owners cannot be verified in discovery, a paid diagnostic or a hold is more suitable than a managed engagement.

Frequently asked questions

Should we prospect the industries with the biggest ad budgets first?

No. Category ad spend is a demand signal. Verify contribution margin, partner need, operational readiness, and measurement at account level.

Which budgets matter before a managed engagement?

In addition to the partner fee, verify media, production, compliance, logistics or patient operations, customer support, and internal staffing.

Is an unready company a bad lead?

It may be too early for managed execution but suitable for a paid diagnostic that can result in launch, remediation, or a hold.

Evidence and sources

Request a 30-minute Fit Call

Review the priorities for your target market and sector with a specialist.